New combo treatment aims to shrink lung tumors before surgery
NCT ID NCT07050056
Summary
This study is testing whether combining an immunotherapy drug (tislelizumab) with targeted radiation before surgery can help shrink or eliminate tumors in people with operable non-small cell lung cancer. The goal is to see if this pre-surgery treatment makes the cancer easier to remove and reduces the chance of it coming back. About 20 participants will receive the drug and radiation, then have surgery, and be monitored for a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Northern People Hospital
RECRUITINGYangzhou, Jiangsu, 225001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.